Scott RequadtVenture Partner at Blackstone
Scott Requadt, JD, MBA, is currently CEO of a privately-held cell therapy company that recently closed a significant financing. Scott was previously a Managing Director at Clarus (now Blackstone Life Sciences), where he sourced, led and managed investments spanning therapeutics, medtech and diagnostics. He remains a Venture Partner at Blackstone Life Sciences. Scott has over 17 years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals (acquired by J&J), and previously practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell. Scott currently also serves on the Boards of ESSA Pharmaceuticals (Nasdaq: EPIX) and VBI Vaccines (Nasdaq: VBIV). He has previously been active on the Boards of Avrobio (Nasdaq: AVRO), Edev s.a.r.l, TyRx (acquired by Medtronic), Catabasis (Nasdaq: CATB), Oxford Immunotec (Nasdaq: OXFD), Link Medicine (acquired by AstraZeneca), and Biolex Therapeutics.